SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-063572
Filing Date
2024-05-22
Accepted
2024-05-22 17:03:23
Documents
2
Period of Report
2024-05-20

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1654
2 EX-24 lxeo-ex24.htm EX-24 10420
  Complete submission text file 0000950170-24-063572.txt   13537
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Issuer) CIK: 0001907108 (see all company filings)

IRS No.: 854012572 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010
Business Address
Otero Jose Manuel (Reporting) CIK: 0002024096 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41855 | Film No.: 24974215